UK’s first remote ultrasound performed over 5G network

BHP founder member University Hospitals Birmingham NHS Foundation Trust (UHB) recently hosted the UK’s first demonstration of a remote-controlled ultrasound scan over a public 5G network, at an event which showcased how 5G can transform healthcare and the emergency services. The demo, in partnership with BT and WM5G, was hosted by the Medical Devices Testing … Continue reading “UK’s first remote ultrasound performed over 5G network”

Experts finalise surgical guidelines that will save thousands of lives worldwide

BHP research experts from the University of Birmingham have convened a gathering of medical professionals in Dubai to finalise international surgical guidelines that will help to save thousands of lives in Low- and Middle-income Countries (LMIC) countries. The National Institute for Health Research Global Health Research Unit on Global Surgery (NIHR GHRU) gathered experts to … Continue reading “Experts finalise surgical guidelines that will save thousands of lives worldwide”

Repurposing or combining therapies could help treat autoimmune diseases

Research led by BHP founder-member the University of Birmingham has found that re-purposing already existing drugs – or combining therapies – could be used to treat patients whose autoimmune diseases are proving difficult to treat. Funded by Versus Arthritis, the research was led by the University’s Institute of Inflammation and Ageing and is published in … Continue reading “Repurposing or combining therapies could help treat autoimmune diseases”

NIHR BioResource launches at BHP

Birmingham’s NIHR BioResource, which has recently launched in the Centre for Rare Diseases (CfRD) at the Queen Elizabeth Hospital Birmingham (QEHB), is now looking for volunteers to join. The BioResource will form part of a national database, which has already recruited more than 140,000 people across the country. Anyone can join the BioResource, with recruitment … Continue reading “NIHR BioResource launches at BHP”

Trialling personalised cancer medicine

The challenge Non-small cell lung cancer is the most common type of lung cancer. However, as it is caused by a range of specific mutations which vary between patients, individuals won’t all respond in the same way to the same treatment. This presents a clear opportunity for the use of precision medicine – however, setting … Continue reading “Trialling personalised cancer medicine”